- About
- Projects
- Column 1
- Animal Health & Veterinary Medicine
- Expanded Access
- FDA Patient Listening Sessions
- Food & Nutrition
- Column 2
- Column 1
- News and Events
- Expanded Access eRequest
2021 Innovations in Regulatory Science Awards
The fifth annual Innovations in Regulatory Science Awards presented by the Reagan-Udall Foundation for the FDA will be held Tuesday, December 14, 2021
RDBA and FDA Foundation Partner to Provide Turnkey Resources to Retail Dietitians - The Associated Press
Today, the Reagan-Udall Foundation for the FDA (FDA Foundation) and the Retail Dietitians Business Alliance (RDBA) jointly launched Supporting Healthier Eating in the New Normal: The Ultimate Retail Dietitians Toolkit.
RDBA and FDA Foundation Partner to Provide Turnkey Resources to Retail Dietitians
(July 23, 2021) Today, the Reagan-Udall Foundation for the FDA (FDA Foundation) and the Retail Dietitians Business Alliance (RDBA) jointly launched Supporting Healthier Eating in the New Normal: The Ultimate Retail Dietitians Toolkit. The toolkit provides retail dietitians with easy-to-share, science-based information for consumers who want to adopt healthier lifestyles.
Food & Nutrition
The Reagan-Udall Foundation for the FDA's work supports FDA’s advancement of the Nutrition Innovation Strategy, promotes actions to reduce preventable death and disease related to poor nutrition. The Foundation is engaging with stakeholders -- including regulators, consumers, and industry -- to further food system strategies that foster industry innovation and change in consumer behavior.
COVID-19 Vaccine Confidence Project - Journal of the American Pharmacists Association
Published in the Journal of the American Pharmacists Association, June 11, 2021,
Throughout much of 2020 and the beginning of 2021, while coronavirus disease 2019 (COVID-19) continued to grow and spread, government and public health officials worldwide
Post-COVID-19 Syndrome: Leveraging the Patient Perspective and Technological Innovations to Enable the Delineation of Effective Treatments - The Journal Drugs
More than 32 million individuals have survived a confirmed COVID-19 viral infection in the USA [1, 2], and a substantial proportion of post-COVID survivors are suffering from prolonged, recurrent, and/or newly emerging symptoms that span across bodily systems and organs [3]. The spectrum of symptoms and disabilities observed in this setting has been alarming and suggests that the “post-COVID syndrome” is a pan-inflammatory disease with highly variable disease expression and consequences [4]. However, accurately and completely characterizing post-COVID syndrome is difficult because many individuals with acute COVID-19 infection were not hospitalized, and therefore were not tracked through standard, in-patient-based data reporting mechanisms to public health authorities [5].